Aligos Therapeutics Inc ALGS.OQ ALGS.O is expected to show a fall in quarterly revenue when it reports results on November 6 for the period ending September 30 2025
The South San Francisco California-based company is expected to report a 60.6% decrease in revenue to $500 thousand from $1.27 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Aligos Therapeutics Inc is for a loss of $1.90 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Aligos Therapeutics Inc is $50.00, about 84.9% above its last closing price of $7.53
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -2.50 | -2.36 | -1.53 | Beat | 35.3 |
Mar. 31 2025 | -2.74 | -2.80 | -2.11 | Beat | 24.6 |
Dec. 31 2024 | -2.50 | -3.40 | Missed | -36.2 | |
Sep. 30 2024 | -2.47 | -2.16 | -3.07 | Missed | -42.3 |
Jun. 30 2024 | -4.00 | -4.00 | 0.80 | Beat | 120 |
Mar. 31 2024 | -4.75 | -4.75 | -5.50 | Missed | -15.8 |
Dec. 31 2023 | -2.75 | -6.75 | -5.50 | Beat | 18.5 |
Sep. 30 2023 | -11.73 | -11.87 | -10.25 | Beat | 13.7 |
This summary was machine generated November 4 at 14:44 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments